KB-1369

Lebrikizumab

45578

Background of Lebrikizumab

Lebrikizumab is a humanized monoclonal antibody that targets interleukin-13 (IL-13), a cytokine implicated in the pathogenesis of several inflammatory diseases, including atopic dermatitis (AD). By binding to IL-13, lebrikizumab inhibits its interaction with the IL-13 receptor, thereby modulating the inflammatory response associated with AD. Lebrikizumab represents an innovative approach to treating atopic dermatitis by targeting the IL-13 pathway. Its progression to phase 3 clinical trials underscores the potential of this monoclonal antibody to become a new treatment option for patients with moderate-to-severe AD.

Specifications

Catalog Number	KB-1369
Antibody Name	Lebrikizumab
Isotype	Human IgG4-S228P, kappa
FC Muations	S228P
Target	IL13
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. (September 2011). "Lebrikizumab treatment in adults with asthma". The New England Journal of Medicine. 365 (12): 1088–98.
"Prous Science Molecule of the Month: Lebrikizumab". Thomson Reuters. October 2011. Archived from the original on 26 October 2011. Retrieved 15 December 2011.